Lymphoma: New Drug Combo Beats Immunotherapy Resistance
New Hope for Rare Cancer: Epigenetic Therapy Boosts Anti-PD-1 Response in NKTL February 29, 2024 – A groundbreaking combination therapy is offering renewed optimism for patients battling relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a particularly aggressive and challenging cancer. Early findings suggest that pairing an epigenetic therapy with an anti-PD-1 antibody significantly enhances … Read more